The purpose of this study is to evaluate the efficacy of the Naridrin in improving nasal congestion.

Open label, randomized, multicenter clinical study. Maximal experiment duration: 2 days; 2 visits. Safety and efficacy evaluation

Inclusion Criteria:

• Participants aged 10-17 years old with clinical symptoms of inflammatory of allergic nasal congestion in at least one nostril due to rhinitis or rhinopharyngitis (cold or flu);
• Signed Consent;
• Participants whose mother, father and / or legal guardian is in accordance with all study purposes and procedures;
• Participants with clinical symptoms of nasal congestion in at least one nostril diagnosed through the Glatzel mirror;
• Participants with minimal score of 2 points in the 0 to 3 scale (Moderate obstruction).

Exclusion Criteria:

• Participation in clinical trial in the year prior to this study;
• Total obstruction of one of the nostrils by other etiologies that are not inflammatory or allergic;
• Infectious bacterial-disease (clinically diagnosed);
• Participants treated with antibiotic or possible antibiotic use due to another medical condition;
• Use of intranasal corticosteroids (7 days prior to the study) or systemic (15 days prior to the study), regarding the plasma half-life of the drug;
• Use of decongestants or antihistamine (intranasal or systemic) in the 03 days prior to the study;
• Use of inhaled drugs (except nasal moisturizers such as saline solution) or treatment with immunosuppressants in the week before the study;
• Participants with septum deviation grade II and III, nasal polyps, severe turbinate hypertrophy, adenoid hypertrophy, or other determining factors for nasal obstruction;
• History of hyperthyroidism or hypertension;
• History of hypersensitivity to the components of the study drugs;
• History of transphenoidal hypophysectomy or oronasal surgery with exposure of the dura-mater;
• Exclusive mouth-breathers patients;
• Participants in chronic drug treatment for allergies (eg vaccines for allergy, cromolyn);
• History of alcohol and / or drug abuse 3 months prior to the study;
• Smokers
• Pregnancy or risk of pregnancy and lactating patients;
• PAny clinical, laboratory that, in the judgment of the investigator, may interfere with the safety of research participants.